Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumor Lymphoma | Drug: CS1003 monoclonal antibody | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 136 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas |
Actual Study Start Date : | October 29, 2018 |
Estimated Primary Completion Date : | May 30, 2020 |
Estimated Study Completion Date : | April 30, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: CS1003 monoclonal antibody |
Drug: CS1003 monoclonal antibody
CS1003 will be administered intravenously every 3 weeks.
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Wendie Yuan | +86 21 61097678 | cstonera@cstonepharma.com |
China | |
Beijing Cancer Hospital | Recruiting |
Beijing, China |
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | January 15, 2019 | ||||||
First Posted Date ICMJE | January 18, 2019 | ||||||
Last Update Posted Date | February 28, 2020 | ||||||
Actual Study Start Date ICMJE | October 29, 2018 | ||||||
Estimated Primary Completion Date | May 30, 2020 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Number of participants with adverse events [ Time Frame: from the day of first dose to 90 days after last dose of CS1003 ] | ||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas | ||||||
Official Title ICMJE | A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas | ||||||
Brief Summary | This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1003 in subjects with advanced solid tumors or lymphoma. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 1 | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE | Drug: CS1003 monoclonal antibody
CS1003 will be administered intravenously every 3 weeks.
|
||||||
Study Arms ICMJE | Experimental: CS1003 monoclonal antibody
Intervention: Drug: CS1003 monoclonal antibody
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE |
136 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | April 30, 2021 | ||||||
Estimated Primary Completion Date | May 30, 2020 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
|
||||||
Listed Location Countries ICMJE | China | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03809767 | ||||||
Other Study ID Numbers ICMJE | CS1003-102 | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||
Responsible Party | CStone Pharmaceuticals | ||||||
Study Sponsor ICMJE | CStone Pharmaceuticals | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE | Not Provided | ||||||
PRS Account | CStone Pharmaceuticals | ||||||
Verification Date | February 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |